Maisonneuve-Rosemont Hospital Research Centre
Innovating in cellular and molecular therapy and regenerative medicine
Dr. Jean-Philippe Lafrance
Nephrologist, Maisonneuve-Rosemont Hospital Research Centre
Associate Professor, Department of Pharmacology and Physiology
Université de Montréal
A hotbed of research and innovation in cellular and molecular therapy and regenerative medicine, the Maisonneuve-Rosemont Hospital Research Centre (CR-HMR) conducts human clinical research in its three major fields of excellence: immunology-oncology, nephrology and vision health. Affiliated with the Université de Montréal, it is part of the CIUSSS de l’Est-de-l’Île-de-Montréal and serves a population of more than 535,000.
With over 200 physician-scientists and more than 30 experienced clinical research teams, the CR-HMR is a well-established research facility. It currently has 140 clinical trials under way, 14 of which are phase l and/or ll trials. These early-stage trials are mainly in hematology-oncology, nephrology, ophthalmology and radiation oncology.
The ability of our physician-scientists to initiate and participate in clinical studies is facilitated by close collaboration with the cutting-edge clinical services in the medical specialties of the major areas of excellence. This ability is also propelled by the institution’s Centre of Excellence in Cellular Therapy (CETC), a GMP-certified centre that is one of the most highly developed and sophisticated in the world and a leading asset for Quebec, as well as by the Centre for Commercialization of Cancer Immunotherapy (C3i), a biotech organization active in the field of cellular therapy.
- Access to all clinical areas, including critical care, as well as to beds for conducting clinical trials;
- Investigational drug management by a dedicated section of the Maisonneuve-Rosemont Hospital pharmacy;
- Medical imaging with the Maisonneuve-Rosemont Hospital’s services and possibility of special interpretation;
- Possibility of drawing up a master service agreement with the institution;
- Informed consent templates preapproved by the ethics review board and ready for customization;
- Legal evaluation department accustomed to dealing with industry-sponsored research projects;
- Competitive authorization times for research projects;
- CETC technical platform: production of viral vectors used in clinical trials;
- Centre for Commercialization of Cancer Immunotherapy – C3i.
Investigators specializing in phase I trials
Dr. Isabelle Brunette – ophthalmology, corneal transplantation
Dr. Lambert Busque – hematology, myeloid leukemias
Dr. Sandra Cohen – stem cell transplant
Dr. Jean-Sébastien Delisle – hematology, cellular therapy
Dr. Isabelle Fleury – hematology, lymphoma
Dr. Silvy Lachance – stem cell transplant
Dr. Jean-Philippe Lafrance – nephrology, pharmacokinetics
Dr. Richard LeBlanc – hematology, multiple myeloma
Dr. Vincent Pichette – nephrology, pharmacokinetics
Dr. Denis Claude Roy – hematology, cellular therapy
Dr. Jean Roy – stem cell transplant
Dr. Michael Yassa – radiation oncology
Clinical research coordinating office
+1-514 252-3400, ext. 3724